Table 5 Comparison of PFS in patients receiving T-DM1 with or without prior treatment with capecitabine and lapatinib
Characteristics | No prior capecitabine and lapatinib n = 39 | Prior capecitabine and lapatinib n = 12 | Total n = 51 |
|---|---|---|---|
Progression | |||
No | 9 (23.1%) | 1 (8.3%) | 10 (19.6%) |
Yes | 30 (76.9%) | 11 (91.7%) | 41 (80.4%) |
PFS according to Kaplan- Meier (months) | |||
Median | 9.17 | 5.56 | 9.01 |
CI95 | (5.42–12.10) | (2.70–28.96) | (4.87–11.41) |
Minimum | 1.1 | 2.7 | 1.1 |
Maximum | 31.1 | 55.4 | 55.5 |
Intergroup comparison (Log-Rank test) | |||
p-value | 0.875 | ||